Name (Synonyms) | Correlation | |
---|---|---|
drug380 | Baricitinib or Anakinra Wiki | 1.00 |
drug611 | Cannabis, Medical Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D000070627 | Chronic Traumatic Encephalopathy NIH | 1.00 |
D016472 | Motor Neuron Disease NIH | 1.00 |
D005879 | Tourette Syndrome NIH | 1.00 |
D012640 | Seizures NIH | 0.71 |
D000755 | Anemia, Sickle Cell NIH | 0.71 |
D001714 | Bipolar Disorder NIH | 0.71 |
D005356 | Fibromyalgia NIH | 0.58 |
D001927 | Brain Diseases NIH | 0.50 |
D010300 | Parkinsonian NIH | 0.50 |
D003424 | Crohn Disease NIH | 0.45 |
D000070642 | Brain Injuries, Traumatic NIH | 0.38 |
D015212 | Inflammatory Bowel Diseases NIH | 0.38 |
D059350 | Chronic Pain NIH | 0.35 |
D001930 | Brain Injuries, NIH | 0.33 |
D012598 | Scoliosi NIH | 0.30 |
D009103 | Multiple Sclerosis NIH | 0.29 |
D040921 | Stress Disorders, Traumatic NIH | 0.19 |
D014947 | Wounds and Injuries NIH | 0.19 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.18 |
D004194 | Disease NIH | 0.17 |
D013577 | Syndrome NIH | 0.10 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006802 | Abnormal anterior horn cell morphology HPO | 1.00 |
HP:0007354 | Amyotrophic lateral sclerosis HPO | 1.00 |
HP:0100754 | Mania HPO | 0.71 |
HP:0001250 | Seizure HPO | 0.58 |
HP:0001298 | Encephalopathy HPO | 0.50 |
HP:0100280 | Crohn's disease HPO | 0.45 |
HP:0002037 | Inflammation of the large intestine HPO | 0.38 |
HP:0012532 | Chronic pain HPO | 0.35 |
There is one clinical trial.
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.
Measure: Treatment of Symptoms Time: Five yearsDescription: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.
Measure: Monitoring Adverse Events Time: Five yearsDescription: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.
Measure: Cannabis Impact on Quality of Life Time: Five yearsDescription: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.
Measure: Cannabis Route and Dosing Time: Five years